New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
06:47 EDTTHRX, GSKGlaxoSmithKline, Theravance announces Australia approval of Anoro Ellipta
GlaxoSmithKline (GSK) and Theravance (THRX) announced that the Therapeutic Goods Administration in Australia has approved Anoro Ellipta as a long-term once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Anoro is a once-daily combination treatment comprising two bronchodilators, umeclidinium, a long-acting muscarinic antagonist, and vilanterol, a long-acting beta2 agonist, in a single inhaler, the Ellipta. The evidence supporting this indication was based upon results of 11 clinical studies in 7,851 patients with COPD.
News For THRX;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
16:50 EDTTHRXTheravance sees results from Salford COPD lung study in 2016
"Results from the SUMMIT chronic obstructive pulmonary disease study of 16,000 patients evaluating the impact of Relvar/Breo Ellipta on all-cause mortality among patients with COPD who have cardiovascular disease are expected to be available by year-end 2015. The Salford lung study in COPD is expected to complete by the end of 2015 with the first results expected in 2016," said the company.
16:48 EDTTHRXTheravance reports Q2 EPS (7c), consensus (6c)
Subscribe for More Information
14:49 EDTGSKGlaxoSmithKline probing new bribery allegations in Romania, Reuters reports
Subscribe for More Information
08:00 EDTGSKGlaxoSmithKline reports Q2 global pharmaceuticals revenue GBP2.98B, down 12%
Reports Q2 HIV revenue GBP559M, up 59%. Reports Q2 Pharmaceuticals revenue GBP3.54B, down 6%, and vaccines revenue GBP814M, up 11%. Consumer healthcare sales were GBP1.51B, up 51% year over year.
07:58 EDTGSKGlaxoSmithKline sees FY16 core EPS to grow in double digits
Subscribe for More Information
07:57 EDTGSKGlaxoSmithKline reaffirms FY15 core EPS declining at high-teens percentage rate
Subscribe for More Information
07:54 EDTGSKGlaxoSmithKline reports Q2 adjusted EPS 17.3p, consensus 16.78p
Subscribe for More Information
July 27, 2015
17:31 EDTGSKRadius Health hires Dr. Lorraine Fitzpatrick as Chief Medical Officer
Radius Health (RDUS) announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline (GSK), responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.
08:03 EDTGSKNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
July 24, 2015
05:04 EDTGSKAgenus reports GSK Malaria vaccine receives positive opinion from CHMP of EMA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use